Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in patients with high-risk early-stage breast cancer. I-SPY2...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Julie E., Forero-Torres, Andres, Yee, Douglas, Yau, Christina, Wolf, Denise, Park, John, Parker, Barbara A., Chien, A. Jo, Wallace, Anne M., Murthy, Rashmi, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Yung, Rachel L., Isaacs, Claudine, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Stringer-Reasor, Erica, Price, Elissa, Joe, Bonnie, Liu, Minetta C., Brown-Swigart, Lamorna, Petricoin, Emanuel F., Wulfkuhle, Julia D., Buxton, Meredith, Clennell, Julia L., Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Symmans, W. Fraser, van ‘t Veer, Laura J., Hylton, Nola M., DeMichele, Angela M., Berry, Donald A., Esserman, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715670/
https://www.ncbi.nlm.nih.gov/pubmed/36456573
http://dx.doi.org/10.1038/s41523-022-00493-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715670/
https://www.ncbi.nlm.nih.gov/pubmed/36456573
http://dx.doi.org/10.1038/s41523-022-00493-z

Ejemplares similares